Source - LSE Regulatory
RNS Number : 3235M
Dechra Pharmaceuticals PLC
20 September 2021



Monday, 20 September 2021



Dechra® Pharmaceuticals PLC

(the Company)

Annual Financial Report



The Company announced its Preliminary Results on 6 September 2021 in accordance with the financial reporting obligations of the Disclosure and Transparency Rules.


Copies of the Annual Report and Accounts for the year ended 30 June 2021, Notice of Annual General Meeting and Proxy Form have now been mailed to shareholders.


In accordance with Listing Rule 9.6.1 a copy of the Annual Financial Report and Notice of Meeting has been submitted to the FCA document viewing facility


The Annual Report and Accounts, Notice of Annual General Meeting and information relating to the voting rights of Shareholders (as required by section 311A of the Companies Act 2006) are available to view on the Company's website Further copies of the Annual Report and Accounts are available from the Company's registered office at:


24 Cheshire Avenue

Cheshire Business Park

Lostock Gralam






Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC

Tel: +44 (0) 1606 814730



About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit:



Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.


Stock Code: Full Listing (Pharmaceuticals): DPH


LEI: 213800J4UVB5OWG8VX82


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.